Log in
NASDAQ:ANIP

ANI Pharmaceuticals Stock Forecast, Price & News

$28.51
-0.44 (-1.52 %)
(As of 10/26/2020 12:00 AM ET)
Add
Compare
Today's Range
$28.07
Now: $28.51
$28.66
50-Day Range
$26.86
MA: $28.82
$30.78
52-Week Range
$25.23
Now: $28.51
$80.87
Volume35,156 shs
Average Volume55,168 shs
Market Capitalization$350.96 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company offers pharmaceuticals for the treatment of breast cancer, hypertension, ventricular arrhythmias, stage D2 metastatic carcinoma of the prostate, depression, diarrhea, infections, vasomotor symptoms of menopause, pain caused by osteoarthritis and rheumatoid arthritis, epilepsy, arrhythmia, obsessive-compulsive disorder and social anxiety disorder, ulcerative colitis, salt and fluid retention, manic episodes of bipolar disorder, ulcerative colitis, proctosigmoiditis, ocular conditions, metastatic prostate cancer, arrhythmia, migraine headache, and enterocolitis caused by staphylococcus aureus. It also provides aspirin and extended-release dipyridamole; Cholestyramine, an adjunctive therapy to diet for the reduction of elevated serum cholesterol; Ezetimibe-Simvastatin to lower high cholesterol and triglyceride levels; Fenofibrate, a peroxisome proliferator receptor alpha activator; Hydrocortisone rectal cream for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Morphine Sulfate, an oral solution for acute and chronic pain management; Nimodipine to enhance neurological outcomes; and Terbutaline Sulfate for the prevention and reversal of bronchospasm. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Read More
ANI Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.09 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANIP
Previous SymbolNASDAQ:BPAX
CUSIPN/A
Phone218-634-3500
Employees338

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$206.55 million
Cash Flow$7.99 per share
Book Value$17.59 per share

Profitability

Net Income$6.09 million

Miscellaneous

Market Cap$350.96 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$28.51
-0.44 (-1.52 %)
(As of 10/26/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

How has ANI Pharmaceuticals' stock been impacted by Coronavirus?

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ANIP shares have decreased by 25.6% and is now trading at $28.51.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ANI Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ANI Pharmaceuticals
.

When is ANI Pharmaceuticals' next earnings date?

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for ANI Pharmaceuticals
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Thursday, August, 6th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.57 by $0.12. The specialty pharmaceutical company earned $48.47 million during the quarter, compared to analysts' expectations of $45.70 million. ANI Pharmaceuticals had a positive return on equity of 20.11% and a negative net margin of 10.27%. During the same quarter last year, the business posted $1.44 earnings per share.
View ANI Pharmaceuticals' earnings history
.

What price target have analysts set for ANIP?

3 Wall Street analysts have issued 1-year price objectives for ANI Pharmaceuticals' shares. Their forecasts range from $40.00 to $58.00. On average, they expect ANI Pharmaceuticals' share price to reach $46.00 in the next year. This suggests a possible upside of 61.3% from the stock's current price.
View analysts' price targets for ANI Pharmaceuticals
.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 551,800 shares, a decrease of 10.4% from the August 31st total of 615,700 shares. Based on an average trading volume of 94,400 shares, the short-interest ratio is presently 5.8 days. Currently, 5.8% of the company's shares are short sold.
View ANI Pharmaceuticals' Short Interest
.

Who are some of ANI Pharmaceuticals' key competitors?

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the following people:
  • Mr. Stephen P. Carey, CFO & VP of Fin. (Age 49, Pay $719.68k)
  • Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 57, Pay $608.59k)
  • Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 48, Pay $724.26k)
  • Mr. Nikhil Lalwani, Pres, CEO & Director

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.55%), LSV Asset Management (0.54%), Regent Investment Management LLC (0.30%), Defender Capital LLC. (0.08%) and Mesirow Financial Investment Management Inc. (0.08%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, David Nash, James G Marken, Meridian Venture Partners Ii L, Patrick D Walsh, Robert W Schrepfer and Thomas Haughey.
View institutional ownership trends for ANI Pharmaceuticals
.

Which institutional investors are selling ANI Pharmaceuticals stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., LSV Asset Management, and Regent Investment Management LLC.
View insider buying and selling activity for ANI Pharmaceuticals
.

Which institutional investors are buying ANI Pharmaceuticals stock?

ANIP stock was purchased by a variety of institutional investors in the last quarter, including Defender Capital LLC., and Mesirow Financial Investment Management Inc.. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash, Patrick D Walsh, and Thomas Haughey.
View insider buying and selling activity for ANI Pharmaceuticals
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $28.51.

How big of a company is ANI Pharmaceuticals?

ANI Pharmaceuticals has a market capitalization of $350.96 million and generates $206.55 million in revenue each year. The specialty pharmaceutical company earns $6.09 million in net income (profit) each year or $4.46 on an earnings per share basis. ANI Pharmaceuticals employs 338 workers across the globe.

What is ANI Pharmaceuticals' official website?

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]

This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.